Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 184

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1B
Chunk 184
---
.51

        Canceled/forfeited

        (10,820
        )
         
        $
        4.51

        Outstanding at December 31, 2024

        —

        $
        —

       As of December 31, 2024, total unrecognized stock-based compensation expense relating to unvested restricted stock units was zero and the weighted-average remaining vesting period was zero years. As of December 31, 2024, all restricted stock awards were vested and none were outstanding.

112

11. Net Loss Per Share The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts):  

        Years Ended December 31,

        2024

        2023

        Numerator:

        Net loss
         
        $
        (63,118
        )
         
        $
        (69,197
        )

        Denominator:

        Weighted average common shares outstanding

        38,210,589

        37,904,318

        Weighted average common stock outstanding subject to repurchase   related to unvested early exercised stock options and   restricted stock awards

        (26,658
        )

        (92,334
        )

        Weighted average common shares outstanding - basic   and diluted

        38,183,931

        37,811,984

        Net loss per share attributable to common stockholders,   basic and diluted
         
        $
        (1.65
        )
         
        $
        (1.83
        )
       
       Potentially dilutive shares to be issued under the ESPP as of December 31, 2024 and 2023 were not included in the calculation of diluted net loss per share because they would be anti-dilutive and were immaterial. In addition, potential dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares): 

        Years Ended December 31,

        2024

        2023

        Common stock options issued and outstanding

        11,423,193

        10,706,541

        Common stock outstanding subject to repurchase related   to unvested early exercised